Effect of Previous Use of Hydroxyurea on the Formation of Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia


chronic myeloid leukemia
tyrosine kinase inhibitors


The objective of the study was to establish the role of prior use of hydroxyurea in shaping of the response to tyrosine kinase inhibitors therapy (TKI) in patients with chronic myeloid leukemia (CML). Patients were divided into 2 groups depending on the duration of the drug application. The first group included 134 patients treated with hydroxyurea no more than 6 months, the second - 253 patients who were treated with these drugs for more than 6 months before the appointment of imatinib. Studies indicate that the previous use of hydroxyurea no more than 6 months leads to the optimal response after 12 months imatinib treatment in (71.6±3.9)% of patients, to suboptimal in (17.2±3.3)%, to treatment failure in (11.2±2.7)% of patients. Study of imatinib treatment in patients who previously received hydroxyurea for more than 6 months, showed that at 12 months therapy the optimal response was achieved in (13.0±2.1)% of patients, suboptimal response defined in (29.6±2.9) %, treatment failure - in (57.3±3.1)%. It is proved that the previous use of hydroxyurea over the 6 months before prescribing TKI leads to poor response to therapy. Thus, hydroxyurea pretreatment >6 months is one of the factors that degrade the results TKI therapy and may be the cause of resistance to treatment.


Lomaya E.G., Tyurin N.S., Zarytskyi A.Y.. The value of timely evaluation of effectiveness imatinib therapy in a patients with chronic myeloleukosis. Ukrainskyi zhurnal hematolohii ta transfusiolohii. 2008; 6 (8): 28-33.

Lomaya E.G., Konopleva M., Romanov E.G., Zarytskyi A.Y. Chronic myeloleukosis - before and after imatinib (part III). Onkohematolohiia. 2010; 1: 5-20.

Abdulkadirov K., Lomaia E., Shuvaev V. [et al.] 6-year experience of treatment by Imatinib in CML patients in 6 million population region of Russia (Saint-Petersburg and Leningrad region) with impact on time anf kind of pretreatment. Blood. 2009; 114 (22); Abstr. 4278.

Dyagil I., Lomaia E., Abdulkadirov K. Busulfan Exposure Decrease CCyR Rate On Imatinib Therapy – Impact On Recent Pretreatment // Blood (ASH) Annual Meeting Abstracts). 2011; 118 (21); Abstract 4452 (online publication).

Giles F.J. New directions in the treatment of imatinib failure and/or resistance. Semin. Hematol. 2009; 46 (3): 27-33.

Huges T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukemia. Blood Rev. 2006; 20 (1): 29-41.

Kantarjian H.M. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008; 112: 837-845.

Zhang W.W., Cortes J.E., Yao H. [et al.] Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol. 2009. 27 (22): 3642-3649.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Download data is not yet available.